학술논문

The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis
Document Type
Journal
Source
MULTIPLE SCLEROSIS AND RELATED DISORDERS; APR 2020, 39 p101863 9p.
Subject
Language
English
ISSN
22110356